Effect of dalargin on the content of goblet cells and mucins in the colonic mucosa in experimental ulcerative colitis
https://doi.org/10.20538/1682-0363-2024-3-59-65
Abstract
Aim. To investigate the protective effect of dalargin on the content of goblet cells and mucins in the colonic mucosa in a mouse model of ulcerative colitis.
Materials and methods. Ulcerative colitis was simulated in Balb/C mice by replacing drinking water with 5% sodium dextran sulfate in boiled water for 5 days. Dalargin was administered subcutaneously in a volume of 0.1 ml at a dose of 100 μg / kg of body weight once a day for 7 days from the beginning of ulcerative colitis simulation. Sulfasalazine as a reference-listed drug was administered intragastrically at a dose of 200 mg / kg once a day for 7 days. The mice were sacrificed on day 5, 7, and 28. The sections of the distal colon were prepared and stained with hematoxylin and eosin, alcian blue (pH = 1.0) according to Mowry or by PAS reaction. In the sections, the number of goblet cells and acid and neutral mucins was determined.
Results. In the mouse model of ulcerative colitis, the number of goblet cells (mainly at the bottom of the crypts), acid and neutral mucins decreased. Dalargin administration increased the number of goblet cells and the content of acid and neutral mucins in the colonic mucosa more effectively than sulfasalazine.
Conclusion. Dalargin has a protective effect in ulcerative colitis.
About the Authors
A. Yu. Liashev
Kursk State Medical University
Russian Federation
Russian Federation
3, Karla Marxa Str., Kursk, 305041
G. S. Mal
Kursk State Medical University
Russian Federation
Russian Federation
3, Karla Marxa Str., Kursk, 305041
A. V. Solin
Belgorod State National Research University
Russian Federation
Russian Federation
85, Pobedy Str., Belgorod, 308015
References
1. Gustafsson J.K., Johansson M.E.V. The role of goblet cells and mucus in intestinal homeostasis. National Review of Gastorenterology and Hepatology. 2022;19(12):785–803. DOI: 10.1038/s41575-022-00675-x.
2. Ma J., Rubin B.K., Voynow J.A. Mucins, mucus and goblet cells. Chest. 2018;154(1):169–176. DOI: 10.1016/j.chest.2017.11.008.
3. Давыдова Е.В., Осиков М.В., Кайгородцева Н.В. Влияние локальной озонотерапии на маркеры активности воспалительного процесса при экспериментальном язвенном колите. Бюллетень сибирской медицины. 2022;21(1):47–53. DOI: 10.20538/1682-0363-2022-1-47-53.
4. Ordás I., Eckmann L., Talamini M., Baumgart D.C., Sandborn W.J. Ulcerative colitis. Lancet. 2012;380(9853):1606– 1619. DOI: 10.1016/S0140-6736(12)60150-0.
5. Du L., Ha C. Epidemiology and pathogenesis of ulcerative colitis. Gastroenterology Clinics of North America. 2020;49(4):643–654. DOI: 10.1016/j.gtc.2020.07.005.
6. Булгаков С.А. Пептидные лекарства в панкреатологии: состояние проблемы и перспективы. Доказательная гастроэнтерология. 2018;7(4):30–34. DOI: 10.17116/dokgastro2018704130.
7. Хомякова Т.И., Золотова Н.А., Хочанский Д.Н., Хомяков Ю.Н. Моделирование острого и хронического колита у мышей. Лечение и профилактика. 2013;7(3):148–159.
8. Мотов В.С., Быкова А.В., Быков В.В., Хазанов В.А., Венгеровский А.И. Протективное действие производного аминогуанидина на модели язвенного колита у крыс. Экспериментальная и клиническая фармакология. 2021;84(5):6–10. DOI: 10.30906/0869-2092-2021-84-5-6-10.
9. Bankhead P., Loughrey B., Fernandez J.A., Dombrowski Y., McArt D.G., Dunne P.D. et al. QuPath: open source software for digital pathology image analysis. Science Reports. 2017;7(1):16878. DOI: 10.1038/s41598-017-17204-5.
10. Ruifrok A.C., Johnston D.A. Quantification of histochemical staining by color deconvolution. Analytic and Quantitative Cytology and Histology. 2001;23(4):291–299.
11. Золотова Н.А., Хочанский Д.Н., Поликарпова А.В., Добрынина М.Т., Макарова О.В. Цитофизиологическая характеристика эпителиальных секреторных клеток разных отделов ободочной кишки при экспериментальном язвенном колите. Клиническая и экспериментальная морфология. 2016;5(2):29–37.
12. Parikh K., Antanaviciute A., Fawkner-Corbett D., Jagielowicz M., Aulicino A., Lagerholm C. et al. Colonic epithelial diversity in health and inflammatory bowel disease. Nature. 2019;7749(567):49–55. DOI: 10.1038/s41586-019-0992-y.
13. Pelaseyed T., Bergstrom J.H., Gustafsson J.K., Ermund A., Birchenough G.M.H., Schutte A. et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunological Reviews. 2014;260(1):8–20. DOI: 10.1111/imr.12182.
14. Anselmi L., Huynh J., Duraffourd C., Jaramillo I., Vegezzi G., Saccani F. et al. Activation of μ opioid receptors modulates inflammation in acute experimental colitis. Neurogastroenterology and Motility. 2015;27(4):509–523. DOI: 10.1111/nmo.12521.
15. Платонова В.В., Севбитов А.В., Шакарьянц А.А., Дорофеев А.Е. Экспериментально-клиническое обоснование лечения больных одонтогенными флегмонами челюстно-лицевой области с использованием в комплексной терапии препарата даларгин. Клиническая и лабораторная диагностика. 2018;63(5):293–296. DOI: 10.18821/08692084-2018-63-5-293-296.
Review
For citations:
Liashev A.Yu., Mal G.S., Solin A.V. Effect of dalargin on the content of goblet cells and mucins in the colonic mucosa in experimental ulcerative colitis. Bulletin of Siberian Medicine. 2024;23(3):59-65. https://doi.org/10.20538/1682-0363-2024-3-59-65
Views:
359
Email this article 